SHL - Sonic Healthcare

 SHL Sonic Healthcare

27/07/26

Worlds largest pathology company.

No 1 pathology company in Australia, Germany, Switzerland, #2 in the UK, #3 in the US.

30 year history of increasing dividends (from 1994). I would classify this as a dividend aristocrat.

https://investors.sonichealthcare.com/investors/?page=dividends

https://investors.sonichealthcare.com/Investors/

https://koalagains.com/stocks/ASX/shl

https://www.marketindex.com.au/asx/shl

https://www.tradingview.com/symbols/ASX-SHL/financials-overview/

https://stockanalysis.com/quote/asx/shl/

..............................

ASX:SHL (Sonic Healthcare) has experienced a steady normalization of earnings over the last 5 years as the massive COVID-19 testing boom receded. While revenues have been supported by acquisitions, statutory net profit has declined from a peak of approx $1.46B in FY2022 to about $514M in FY2025. [1, 2, 3, 4, 5]

Financial Snapshot

• Profit: Net profit dropped from its pandemic peak to roughly $513.6M for FY2025. In the 12 months leading into 2026, the company generated revenues of $10.42B with annualized profits of about $539M. [1, 2, 3]

• Debt: The company maintains a conservative balance sheet. As of recent 2026 periods, long-term debt sits near $3.87B (net debt), representing a manageable Debt/Equity ratio of approximately 56% to 68%. Interest coverage remains solid at around 5 to 10 times
• https://simplywall.st/stocks/au/healthcare/chia-shl/sonic-healthcare-shares/health
• . [1, 2, 3, 4]

https://stockanalysis.com/quote/asx/shl/financials/ratios/

D/E ratios

2026 - 0.68

2025 - 0.61

2024 - 0.56

2023 - 0.39

2022 - 0.41

2021 - 0.50

• ROE: Return on Equity (ROE) has compressed to the 6% - 7% range as equity expanded and pandemic-era margins (which previously exceeded 15% normalized down to around 5.2%. [1, 2, 3]

..............................

Over the last 10 years, Sonic Healthcare Limited (ASX: SHL) has traded at a 10-year median P/E ratio of 21.53, with its current Trailing Twelve Month (TTM) P/E ratio sitting slightly lower near 19.1x to 19.8x. [1, 2]

The company's valuation underwent significant volatility during the COVID-19 pandemic. A massive surge in diagnostic testing revenues temporarily supercharged its earnings per share (EPS), driving the P/E ratio down to a historical 10-year low of 9.51 in 2022. As pandemic-related testing revenues normalized and operational expenses increased, the multiple contracted and later normalized back toward its historical average. [1, 3]

---

10-Year Historical P/E Ratio Data

The tracking below outlines the historical P/E multiples for Sonic Healthcare at the end of each fiscal period: [1, 2, 3, 4]

Year	P/E Ratio (As of June End)	Key Valuation Context
2026 (Current TTM)	~19.1x – 19.8x	Stabilizing post-COVID; trading slightly below historical median.
2025	24.3x – 25.1x	Core business returns to growth, but compressed margins lift the multiple.
2024	24.9x – 26.2x	Earnings drop faster than the share price as COVID backlogs clear out.
2023	19.7x – 24.5x	Transition period away from government-mandated respiratory testing.
2022	10.6x	10-Year Low. Peak pandemic testing created record-high global profits.
2021	14.0x – 16.2x	Early vaccine rollouts and massive testing volumes fuel earnings growth.
2020	24.4x	Initial pandemic disruptions offset by high long-term defensive demand.
2019	24.7x	Standard baseline trading range for ASX healthcare infrastructure.
2018	25.1x	Stable earnings performance across domestic and global lab networks.
2017	23.5x	Reflects defensive, high-quality healthcare market premium.
2016	21.3x	Aligned closely with the long-term 10-year historical mean.

---

Important Metrics to Note

10-Year Range: Minimum of 9.51 (2022) to a maximum of 34.19 (intra-year peak).
10-Year Median: 21.53.
Earnings Trajectory: Analysts tracking GuruFocus historical data and Yahoo Finance point to a Forward P/E closer to 14.9x – 16.7x, driven by anticipated margin recovery as base pathology volumes expand and global acquisitions begin contributing to top-line earnings. [1, 2, 4, 5]

...................

Sonic Healthcare's (Sonic Healthcare) current (2026) Return on Invested Capital (ROIC) is roughly 4.68% to 5.09%, which trails its Weighted Average Cost of Capital (WACC) of roughly 7.87% to 7.98%. Over the past 10 years, normalization post-pandemic and rising interest rates have compressed the historical spread, leaving recent ROIC below the 10-year median WACC. [1, 2, 3]

Profitability vs Financing Cost

Current ROIC: ~4.68% (trailing twelve months)
Current WACC: ~7.87%
10-Year WACC Median: ~5.41% (historical costs averaged lower over the prior decade prior to recent rate hikes)
Value Creation Spread: Negative in the short-term trailing period, as current returns lag the blended cost of capital. [1]

Historical Context & Nuance

Pandemic Surge: During the COVID-19 pandemic years, testing volumes artificially inflated earnings and ROIC well above historical averages. [1]
Normalization: As pandemic testing windfalls receded and capital investments (alongside higher global interest rates) pushed up the WACC, Sonic Healthcare’s ROIC normalized downward. [1, 2]
Capital Discipline: The company's management continues to target ROIC accretion through organic growth and efficiency initiatives, though current metrics indicate a period where marginal capital returns sit below hurdle rates. [1, 2]

................................